A new 3D bioprinted model offers a novel tool to study common liver disease, and perhaps find an effective treatment

Metabolic dysfunction–associated steatohepatitis or MASH (formerly known as nonalcoholic steatohepatitis) is an inflammatory, liver-scarring disease that affects 1.5% to 6.5% of all U.S. adults. There are no approved pharmacological therapies for MASH and in the most severe case, the only recourse is liver transplantation.

​Metabolic dysfunction–associated steatohepatitis or MASH (formerly known as nonalcoholic steatohepatitis) is an inflammatory, liver-scarring disease that affects 1.5% to 6.5% of all U.S. adults. There are no approved pharmacological therapies for MASH and in the most severe case, the only recourse is liver transplantation. Metabolic dysfunction–associated steatohepatitis or MASH (formerly known as nonalcoholic steatohepatitis) is an inflammatory, liver-scarring disease that affects 1.5% to 6.5% of all U.S. adults. There are no approved pharmacological therapies for MASH and in the most severe case, the only recourse is liver transplantation.